Table 3. Description of adverse event reports following receipt of seasonal influenza vaccine-type, N=389a.
| Report descriptor | Influenza vaccine type | ||||
|---|---|---|---|---|---|
| IIV3-Adj | IIV4-SD | IIV4-HD | IIV4-cc | LAIV-4 | |
| Total reports | Fewer than 10 | 296 | 79 | Fewer than 10 | Fewer than 10 |
| Non-serious | SDC | 262 | 67 | SDC | SDC |
| Serious | SDC | 34 | 12 | SDC | SDC |
| Proportion serious | SDC | 11.5% | 15.2% | SDC | SDC |
| Total doses distributed | 69,587 | 13,456,161 | 1,876,475 | 34,533 | 168,420 |
| Reporting rate (95% CI)b | SDC | 2.2 (2.0–2.5) | 4.2 (3.3–5.2) | SDC | SDC |
| Serious rate (95% CI) | SDC | 0.3 (0.2–0.4) | 0.6 (0.3–1.1) | SDC | SDC |
Abbreviations: CI, confidence interval; IIV3-Adj, adjuvanted egg-based trivalent inactivated influenza vaccine; IIV4-cc, standard-dose cell culture-based quadrivalent inactivated influenza vaccine; IIV4-HD, high-dose egg-based quadrivalent inactivated influenza vaccine; IIV4-SD, standard-dose egg based quadrivalent inactivated influenza vaccine; LAIV4, quadrivalent live attenuated influenza vaccine; SDC, statistical disclosure control (suppression of small cell counts)
a Fifty-seven reports with missing influenza vaccine name and type, and two reports with vaccines distributed in previous season were excluded
b Rates were calculated per 100,000 doses distributed